Navigation Links
Experts Compare Colon Cancer Treatment Outcomes
Date:9/21/2007

Review of studies shows big survival gains

THURSDAY, Sept. 20 (HealthDay News) -- The current chemotherapy regimens of irinotecan, oxaliplatin, and molecular-targeted treatments are helping patients with advanced colorectal cancer live several months longer than they did a few years ago, when these therapies weren't available, Greek researchers say.

Researchers at the University of Ioannina School of Medicine performed a meta-analysis of 242 studies on these chemotherapies, conducted over the past 40 years.

The study was published online Thursday in The Lancet Oncology journal.

Previous studies have noted survival benefits for patients receiving the newer regimens, but the degree of these benefits across assorted regimens has been less clear, the team said.

They conducted the meta-analysis to examine whether certain treatment regimens for advanced colorectal cancer offer better survival and delayed disease progression and to determine the extent of such benefits.

According to the study, among patients who would be expected to live for one year when treated with the drugs fluorouracil and leucovorin, there was an estimated absolute survival benefit of an extra eight months if patients received additional treatment with irinotecan plus bevacizumab.

The researchers also concluded that the addition of oxaliplatin plus bevacizumab or irinotecan plus oxaliplatin offered four to seven additional months of survival for patients.

However, the researchers also noted that multidrug combinations that improve survival can cause serious toxic side effects. They called for long-term follow-up data on toxicity associated with these treatments.

"The fluorouracil, leucovorin, irinotecan, plus bevacizumab regimen especially, which has the highest probability to be the best in improving survival according to our analysis, might be complicated by up to 84.9 percent of grade 3 or 4 adverse events, including a 1.5 percent chance of gastrointestinal perforation," the researchers noted. "(These) existing uncertainties suggest that more data are needed, especially for the newest regimens", they said.

More information

The American Cancer Society has more about colorectal cancer treatment decisions.



-- Robert Preidt



SOURCE: The Lancet Oncology, news release, Sept. 20, 2007


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Smoking a greater risk than HIV? Yes say health experts!!!!
2. Good carb, bad carb? Experts debate.
3. Serevent, to be examined by experts due to deaths associated with its use
4. Spread Of Rocky Mountain Spotted Fever Is A Probability, Say Experts
5. Experts Recommend Preventive Measures For Avian Flu To Begin From Farms
6. Experts Insist That Neonatal Herpes Be Reported Regularly
7. Experts State Strategies To Increase Good Cholesterol
8. Speed up bird flu vaccine, Bush tells experts
9. Tennis elbow not new among cricketers, say experts
10. Cancer Can Recur Any Time, Experts Caution
11. Experts Building Bird Flu Warning System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2017)... ... February 19, 2017 , ... Braun Industries will be ... & Exposition, the event will take place February 23-25, 2017 at the Calvin L. ... in Booth #909 with three new ambulances on display. , “JEMS ...
(Date:2/18/2017)... ... February 17, 2017 , ... Focused start-ups, not ... the industry, according to the recent NEJM Catalyst Insights Report on the New ... NEJM Catalyst Insights Council, a qualified group of U.S. executives, clinical leaders, and ...
(Date:2/18/2017)... ... February 18, 2017 , ... A new directory from ... points to easily connect elderly veterans of America's armed forces to a range ... also conveys material on this year's increase in the Veterans Pension with Aid ...
(Date:2/17/2017)... ... 2017 , ... For the first time, International Scholarship and ... floor for the 2017 HIMSS Conference & Exhibition at the Orange ... than 40,000 healthcare industry professionals are expected at the conference, where they will ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... the HIMSS17 Conference & Exhibition in Orlando, Fla., February 19-23. Visitors to the ... the most widely used electronic patient signatures solution in healthcare . ...
Breaking Medicine News(10 mins):
(Date:2/18/2017)... -- Research and Markets has announced the addition of the ... ... comprehensive analytics for the US, Canada , ... , Latin America , and Rest of World. Annual ... a six-year historic analysis is provided for these markets. Market data and ...
(Date:2/17/2017)... NEW HAVEN, Conn. , Feb. 17, 2017 /PRNewswire/ ... new class of drugs based on protein degradation, today ... oral androgen receptor (AR) PROTAC during a poster session ... Cancers Symposium (ASCO GU) in Orlando, FL. ... today continue to validate our platform and the potential ...
(Date:2/17/2017)... 2017   Risperdal lawsuits involving gynecomastia (male breast ... use of the atypical antipsychotic medication continue to move ... of Common Pleas, where the state,s Risperdal docket has ... a notice posted on the Court,s website , ... March 9, 2017 at 11:00 a.m. (In Re: Risperdal ...
Breaking Medicine Technology: